Brand name : NAMENDA
US FDA Approval :October 2003
NMDA (N-methyl-D-aspartate) receptor antagonist
Indicated for the treatment of moderate to severe Alzheimer’s Disease
VILDAGLIPTIN: DPP-IV INHIBITOR
Generic name: Vildagliptin
Brand name: Galvus
Treatment for: type 2 diabetes
selective inhibitor of dipeptidyl-
peptidase IV (DPP-IV)
- the first in a new class of oral antidiabetic agents
- known as dipeptidyl peptidase IV inhibitors
(DPP-IV) inhibitors
Tarceva® ( erlotinib )
Indicated for :the treatment of locally advanced or metastatic non-small cell lung cancer that has failed prior chemotherapy
Human Epidermal Growth Factor Receptor Type 1/Epidermal Growth Factor Receptor (HER1/EGFR) tyrosine kinase inhibitor